Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 24, 2003, Pages 4389-4393

  Suh, Young Ger ^a   Lee, Yong Sil ^a   Min, Kyung Hoon ^a   Park, Ok Hui ^a   Seung, Ho Sun ^a   Kim, Hee Doo ^b   Park, Hyoung Geun ^a   Choi, Ji Yeon ^a   Lee, Jeewoo ^a   Kang, Sang Wook ^a   Oh, Uh Taek ^a   Koo, Jae Yeon ^a   Joo, Yung Hyup ^c   Kim, Sun Young ^c   Kim, Jin Kwan ^c   Park, Young Ho ^c  

^a Seoul National University   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c AmorePacific Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CALCIUM CHANNEL; CAPSAICIN; CAPSAZEPINE; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MK 056; RESINIFERATOXIN; SC 0030; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CALCIUM TRANSPORT; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; MOUSE; NEWBORN; NONHUMAN; RAT; STRUCTURE ANALYSIS;

EID: 0344064842     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.024     Document Type: Article

References (14)

1. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julis D. Nature. 389:1997;816.
2. (a) Szallasi A., Blumberg P.M. Pharmacol. Rev. 51:1999;159 (b) Kress M., Zeilhofer H.U. Trends Pharmacol. Sci. 20:1999;112.
3. (a) Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Nature. 400:1999;452 (b) Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. Br. J. Pharmacol. 129:2000;227.
4. Hwang S.W., Cho H., Kwak J., Lee S.Y., Kang C.J., Jung J., Cho S., Min K.H., Suh Y.G., Kim D., Oh U. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6155.
5. Tominaga M., Caterina M.J., Malmberg A.B., Rosen T.A., Gilbert H., Skinner K., Raumann B.E., Basbaum A.I., Julius D. Neuron. 21:1998;531.
6. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., Harries M.H., Latcham J., Clapham C., Atkinson K., Hughes S.A., Rance K., Grau E., Harper A.J., Pugh P.L., Rogers D.C., Bingham S., Randall A., Sheardown S.A. Nature. 405:2000;183.
7. (a) Park H., Park M., Choi J., Choi S., Lee J., Suh Y., Oh U., Lee J., Kim H., Park Y., Jeong Y.S., Choi J.K., Jew S. Bioorg. Med. Chem. Lett. 13:2003;197 (b) Park H., Park M., Choi J., Choi S., Park B., Kim M., Suh Y., Cho H., Oh U., Lee J., Kim H., Park Y., Koh H., Lim K.M., Mo J., Jew S. Bioorg. Med. Chem. Lett. 13:2003;601 (c) Yoon J.H., Choi H., Lee H.J., Ryu C.H., Park H., Suh Y., Oh U., Jeong Y.S., Choi J.K., Park Y., Kim H. Bioorg. Med. Chem. Lett. 13:2003;1549.
8. Planells-Cases R., Aracil A., Merino J.M., Gallar J., Perez-Paya E., Belmonte C., Gonzalez-Ros J.M., Ferrer-Montiel A.V. FEBS Letter. 481:2000;131.
9. Wahl P., Foged C., Tullin S., Thomsen C. Mol. Pharmacol. 59:2001;9.
10. Wang Y., Szabo T., Welter J.D., Toth A., Tran R., Lee J., Kang S.U., Suh Y.-G., Blumberg P.M., Lee J. Mol. Pharmacol. 62:2002;947. The compound designations, KJM429 and JYL1421 for the analogues 5 and 14 have been changed to MK056 and SC0030, respectively. (Published erratum appears in Mol. Pharmacol. 2003, 63, 958.).
11. Wood J.N., Winter J., James I.F., Rang H.P., Yeats J., Bevan S. J. Neurosci. 8:1988;3208.
12. Dewey W.L., Harris L.S., Howes J.F., Nuite J.A. J. Pharmacol. Exp. Ther. 175:1970;435.
13. The detailed structure-actitvity relationship of SC0030 will be reported in due courses.
14. Santos A.R.S., Calixto J.B. Neurosci. Lett. 235:1997;73.